Did you mean?
Search Results - Showing 36 - 48 Of 50
_results-of-the-myeloma-xi-study-a-quadruplet-regimen-for-transplant-eligible-patients.webp "Dr Charlotte Pawlyn speaks to ecancer at ASH 2018 about the results of the Myeloma XI study. nnThe work being presented was focused on results from the comparison between a quadruplet regimen comprising of carfilzomib, cyclophosphamide, lenalidomide, and dexamethasone (KCRD) vs an immunomodulatory agent containing triplet (CTD/CRD) induction therapy for transplant eligible patients. nnDr Pawlyn explains that the results showed that the quadruplet led to deeper responses and prolonged progression")
⏲ 2 min 34 sec ✓ 03-Dec-2018
_talquetamab-plus-daratumumab-for-rrmm-trimm-2-update.webp "Dr Dholaria talks to ecancer at ASCO 2023 about an update from the TRIMM-2 study he presented in Chicago.nnThis showed that steroid-sparing talquetamab plus daratumum showed deep and durable responses with promising mPFS in heavily pretreated patients with relapsed/refractory multiple myleoma, including in patients refractory to anti-CD38/BCMA and T-cell redirecting therapy.nnThis suggested that combined immunomodulatory actions can yield robust responses in patients with refractory disease.nnTh")
_lenalidomide-with-rituximab-for-mantle-cell-lymphoma.webp "Prof Ruan speaks with ecancer at the ASH 217 annual meeting about 5 year follow-up data from a trial of immunomodulatory induction therapy for mantle cell lymphoma patients.nnThe median age among the 38 patients involved in this trial was 65.nnShe describes the results as consistent with existing safety, efficacy and survival data from a 2015 interim analysis, and describes the management of adverse events including infections and neutropenia.nnProf Ruan notes that, our of patients who developed")
_brentuximab-vedotin-as-salvage-therapy-for-men-with-relapsed-germ-cell-tumours.webp "Dr Necchi talks to ecancertv at ASCO GU 2016, about his work on an open-label, single-group, phase II study of brentuximab vedotin as salvage therapy for males with relapsed germ-cell tumours.nnThe results showed that brentuximab has potent antitumour activity and meaningful immunomodulatory effects in germ-cell testicular tumours.")
⏲ 1 min 47 sec ✓ 10-Oct-2017
_relapse-and-retreatment-of-multiple-myeloma.webp "Prof Heinz Ludwig and Dr Sergio Giralt talk to ecancertv at IMW 2013.nnThe approach to managing relapse in multiple myeloma (MM) has changed dramatically in the last 10-15 years. The choice of therapy has expanded to include novel therapies, but will still depend on the patient group, whether they are healthy elderly, elderly frail or relapsing after a transplant, and whether they are symptomatic or asymptomatic. The present of comorbidities, renal failure and previous experience of toxicities,")
_teclistamab-plus-talquetamab-targeting-bcma-and-gprc5d-shows-promising-efficacy-in-patients-with-rrmm.webp "Dr Yael Cohen speaks to ecancer about the first results from the RedirecTT-1 study. The study investigated teclistamab (tec) + talquetamab (tal) targeting BCMA and GPRC5D in patients with relapsed/refractory multiple myeloma (RRMM).nnDr Cohen notes that the study enrolled patients with relapsed/refractory multiple myeloma or those intolerant to the last line of therapy, patients who were exposed to a proteasome inhibitor, immunomodulatory drug, and anti-CD38 therapy; and those who had measurable")
⏲ 3 min 19 sec ✓ 03-Jun-2023
_multiple-myeloma-new-rescue-options-for-patients-after-front-line-therapy.webp "New approaches to treating patients after eventual failure of initial therapy for multiple myeloma were discussed at the EHA by Paul Richardson who described how the novel agents such as thalidomide and bortezomib can be re-used in patients already shown to be sensitive in front-line therapy, and how there are now other options to follow on.He gives ecancer tv his assessment of the state of the art of rescue therapy using existing treatments, seond and third generation immunomodulatory drugs a")
⏲ 3 min 57 sec ✓ 18-Jan-2018
_chronic-lymphocytic-leukaemia-a-new-treatment-era-is-born.webp "Dr Gribben talks to ecancertv at ASH 2013 about a session covering the latest for CLL treatment.nnThis session focused on recent advances in the management of chronic lymphocytic leukaemia (CLL). The most recent, targeted drugs for CLL, as well as therapeutic concepts for elderly, non-fit patients with CLL and immunotherapeutic approaches to achieve long-lasting remissions were discussed.nnDr Michael Hallek reviewed the currently available diagnostic and therapeutic tools and give an integrated")
_paul-richardson-md-on-melphalan-flufenamide-with-dexamethsane-for-patients-with-mm.webp "Paul Richardson, MD, talks melphalan flufenamide in combination with dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior lines of therapy and whose disease is refractory to at least 1 proteasome inhibitor, 1 immunomodulatory agent, and 1 CD38-directed monoclonal antibody.")
⏲ 5 min 25 sec ✓ 04-May-2021
_id-screening-prior-to-systemic-immunomodulatory-therapy-in-hs-consensus-guidelines-from-asia-pacific-hs-foundation-joh.webp "ID Screening Prior to Systemic Immunomodulatory Therapy in HS: Consensus Guidelines from Asia-Pacific HS Foundation - John Frew from immunomodulatory therapy")
⏲ 5 min 37 sec ✓ 26-Oct-2023
_application-of-balsam-citopsor-review-what-helps-with-psoriasis-how-to-treat-psoriasis.webp "Citopsor | Very effective treatment for psoriasis | Natural ingridientsnnBalsam Citopsor is an innovative non-hormonal solid oil preparation for topical use, which heals the skin in dermatoses (psoriasis, eczema, lichen). The drug effectively neutralizes the pathological manifestations - desquamation, itching and bleeding. It has anti-inflammatory, antibacterial, regenerating, antipruritic, analgesic and immunomodulatory effects at a deep level.nAccording to dermatologists:")
⏲ 1 min 20 sec ✓ 28-Mar-2019
_benefits-of-maintenance-therapy-for-multiple-myeloma.webp "Prof Gareth Morgan speaks about research demonstrating that maintenance therapy with IMiD (immunomodulatory) drugs reduces rates of relapse in multiple myeloma patients and leads to benefits in terms of survival. The low toxicity profile of these drugs allows patients to be treated over a long periods of time without a significant reduction in quality of life. Although research into thalidomide maintenance was not successful, researchers were able to learn a number of lessons which are proving u")
![[+]](/images/menu.gif){kind=small}